By developing a novel digital pathology approach assessing STING on IHC sections, and subsequently identifying a gene signature to classify pnSTINGhigh/low cancers, we were able to validate our finding of poor prognosis in pnSTINGlow ER + breast cancer in both chemotherapy and hormone therapy-treated tumors. This evidence concerns the gene ESR1 and breast cancer.